medigraphic.com
ISSN 0016-3813 (Print)

2007, Number 1

<< Back Next >>

Gac Med Mex 2007; 143 (1)

Características de la prescripción de analgésicos antiinflamatorios no esteroideos en adultos mayores

Lagunes-Espinosa AL, Peralta-Pedrero ML, Rodríguez-Moctezuma R, López-Carmona JM, Ibarra-Vicens E, Cruz-Avelar A, Murguía-Miranda C

Language: Spanish
References: 32
Page: 5-9
PDF size: 51.75 Kb.


ABSTRACT

Objective. Determine prescription characteristics of non-steroidal anti-inflammatory drugs among the elderly attending primary medical care.
Material and methods. Setting, Family Health Unit 52, Mexican Institute of Social Security. Design: Prospective, cross-sectional, descriptive, with randomized sampling. Participants: 400 patients; aged 60 and older, male and female, without cognitive impairment. Those without clinical records were excluded. Every patient was interviewed and examined and their clinical record and prescription were assesed.
Results. NSAIDs were prescribed in 312 patients (78% 95% CI 74- 82), one type of NSAIDs was prescribed in 188 (60% 95%CI 55-65), two types in 117 (38% 95%CI 33-43) and three types in 7 (2% 95%CI 0.0-4). Of the 443 prescriptions, Acetylsalicylic acid was prescribed in 200 cases (45% 95%CI 40-50) and Naproxen in 100 (23% IC95%19-26). Reasons for prescribing included cardiovascular prophylaxis in 46% (IC95% 7-13) pain management in 40% (95%CI 31-49), anti-inflammatory cases 4%(95%CI 2-6), and non-specified in 10% of cases (95%CI 7-13). Treatment duration was not specified for 253 patients (81% 95%CI 77-85). We noted drug-drug interaction in 228 cases (73% 95%CI 67-77) and a potential drug-disease interaction in 247 (79% 95%CI 77-81). The gastro-esophageal prescription was not more frequent among patients taking NSAIDs compared with non-users OR = 1 (95%CI 0.53-1.75; p=0.89).
Conclusions. NSAIDs prescription prevalence is high: although diagnoses do not justify their use and gastro-esophageal protection is often not sufficient. Prostaglandins inhibitors are favored without taking into account drug-disease interaction.


REFERENCES

  1. Organización de las Naciones Unidas. Informe de la Segunda. Asamblea Mundial Sobre Envejecimiento, Madrid España, abril 2002.

  2. Instituto Nacional de Estadística Geografía e Informática, Estados Unidos Mexicanos. XII Censo General de Población y vivienda 2000.

  3. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivela SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002;809-817.

  4. Arbas E, Garzon R, Suárez A, y cols. Consumo de medicamentos en mayores de 65 años: problemas potenciales y factores asociados. Aten Primaria 1998; 22:165-170.

  5. Pirmohamed M, James S, Meakin S, Green Ch, Scott AJ, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19.

  6. Rathore SS, Mehta SS, Boyko WL, Schulman KA. Prescription medication use in older Americans: a national report card on prescribing. Fam Med 1998;30:733-739.

  7. Tomas MT, Centelles F, Valero C. y cols. Prescripción crónica de fármacos de pacientes geriátricos en un centro de salud urbano. Aten Primaria 1999;23:121-126.

  8. Herrador MP, Castillo PA. Estudio del consumo de fármacos en la Residencia del IMSERSO de Melia. Resp Esp Geriatr Gerontol 2002;37:134-140.

  9. Tannenbaum H, Davis P, Russell AS, Atrinson MH, Maksymowyo et al. An evidence-base approach to prescribing NSAIDS in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants. Can Med Assoc J 1996;15:77-88.

  10. Goodman GA, Goodman L, Gilman A. Las bases farmacológicas de la terapéutica.10ed.McGraw-Hill Book Company 2001.

  11. García-Zenón T, López-Guzmán J, Roldán-de-la-O I, Almeida-Alvarado J, kVillalobos A, D’Hyver C. Fármacos inapropiados en el anciano: una propuesta de clasificación. Med Int Mex 2005;21:188-189.

  12. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.

  13. Distribución de los adultos mayores según ingreso en salarios mínimos por sexo y entidad federativa en: Indicadores Demográficos para Adultos 2000-2050. Consejo Nacional de Población, México.

  14. Huang S. Rheumatology: 7 Basics of therapy. Can Med Assoc J 2000;163:417-423.

  15. Schnitzer TJ. Non-NSAID Pharmacologic treatment options for the management of chronic pain. Am J Med 1998;105:45S-52S.

  16. Ruoff G. Management of pain in patients with multiple health problems: a guide for the practicing physician. Am J Med 1998;105:53S-60S.

  17. Pérez Gutthanns, García-Rodríguez LA, Raiford DS, Duque-Oliazt A, Ris- Romeu J. Nonsteroidal anti-inflammatory drugs and de risk of hospitalization for acute renal failure. Arch Intern Med 1996;156:2433-2439.

  18. Griffin MR, Yared A, Wayne R. Nonsteroidal Ant- inflammatory Drugs and acute Renal Failure in Elderly Persons. Am J Epidemiol 2000;15:488-496.

  19. Field T, Gurwitz J, Glynn R, Salive ME, Gaziano JM, Taylor JO, Hennekens CH. The Renal Effects of Nonsteroidal Anti-inflammatory Drugs in Older People: Findings from the Established Populations for Epidemiologics Studies of the Elderly. J Am Geriatric Soc 1999;475:507-511.

  20. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of Antihypertensive Treatment During Nonsteroidal Anti-inflammatory Drug Therapy. JAMA 1994:272:781-786.

  21. PageJ, Henry D. Consumption of NSADs and the Development of Congestive heart Failure in Elderly Patients: An Under recognized Public health Problem. Arch Intern Med 2000:16:777-784.

  22. Rolka DB, Fagot-Campagna A, Venkat KM. Aspirin Use among Adults with Diabetes. Diabetes Care 2001;24:197-201.

  23. Krein SL, Vijan S, Pogach LM, Hogan MM, Keer EA. Aspirin Use and Counseling, About Aspirin among Patients with Diabetes. Diabetes Care 2001;25:965-970.

  24. Blasco V M, Lucia C J. Revisión de los antiagregantes plaquetarios y sus indicaciones en atención primaria. Ocho años después... Aten Primaria 2003;31:252-263.

  25. López de la Iglesia J, Escudero S, González GA, et al. Empleo de antiagregantes en la prevención primaria y secundaria cardiovascular del diabético en el medio urbano y rural del área de León. Aten Primaria 2003;31:361-365.

  26. Pérez S, García RLA, Raiford DS, Duque OA, Ris RJ. Nonsteroidal Antiinflamtory Drugs and the Risk of Hospitalization for Acute Renal Failure. Arch Intern Med 1996;56:2433-2439.

  27. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: Prophylactic and therapeutic strategies. Am J Med 1994;96:274-281.

  28. Dios del Valle R, Hernández SA, Franco-Vidal A González-Rubio y, Romera Fernández I. Prescripción de antinflamatorios no esteroideos y protectores gástricos en urgencias. Aten Primaria 2003;31:500-505.

  29. Griffin M. Epidemiology of nonsteroidal antiinflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:23S-29S.

  30. Hollenz M, Stolte M, Leodolter A, Labenz J. NSAID associated dyspepsia and ulcers: a prospective cohort study in primary care. Dig Dis 2006;24:189-194.

  31. Oparil S, Zaman MA, Calhoun D. Pathogenesis of Hypertension. Ann Intern Med 2003;139:761-776.

  32. Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-2572.




2020     |     www.medigraphic.com